TY - JOUR
T1 - MACOP-B regimen followed by involved-field radiation therapy in early-stage aggresive non-Hodgkin's lymphoma patients
T2 - 14-year update results
AU - Zinzani, P. L.
AU - Stefoni, V.
AU - Tani, M.
AU - Barbieri, E.
AU - Albertini, P.
AU - Vigna, E.
AU - Gherlinzoni, F.
AU - Alinari, L.
AU - Galuppi, A.
AU - Pileri, S.
AU - Babini, L.
AU - Tura, S.
PY - 2001
Y1 - 2001
N2 - A single-center, retrospective study was conducted to evaluate therapeutic results of the MACOP-B third-generation chemotherapy regimen followed by involved-field radiation therapy in a stage I-II aggressive non-Hodgkin's lymphoma (NHL) patients. From 1986 to 1995, 118 consecutive patients with the diagnosis of aggressive NHL, stage I-IE or II-IIE, with or without bulky disease were treated with MACOP-B regimen followed, when appropriate, by 30-36 Gy involved-field radiation therapy The complete response (CR) rate was 95% after the combined modality treatment (97% for stage I-IE and 93% for stage II-IIE). Patients with bulky disease had a CR rate of 92%. Treatment was well tolerated and no deaths occurred from acute toxicity. After a median follow-up of 68 months, 24 (21%) patients relapsed. The 14-year projected relapse-free and overall survival rates were 78% and d 69%, respectively. MACOP-B regimen with/without involved-field radiation therapy provides a safe and effective combined modality treatment for early-stage aggressive NHL, with the possibility to definitively cure two thirds of the patients.
AB - A single-center, retrospective study was conducted to evaluate therapeutic results of the MACOP-B third-generation chemotherapy regimen followed by involved-field radiation therapy in a stage I-II aggressive non-Hodgkin's lymphoma (NHL) patients. From 1986 to 1995, 118 consecutive patients with the diagnosis of aggressive NHL, stage I-IE or II-IIE, with or without bulky disease were treated with MACOP-B regimen followed, when appropriate, by 30-36 Gy involved-field radiation therapy The complete response (CR) rate was 95% after the combined modality treatment (97% for stage I-IE and 93% for stage II-IIE). Patients with bulky disease had a CR rate of 92%. Treatment was well tolerated and no deaths occurred from acute toxicity. After a median follow-up of 68 months, 24 (21%) patients relapsed. The 14-year projected relapse-free and overall survival rates were 78% and d 69%, respectively. MACOP-B regimen with/without involved-field radiation therapy provides a safe and effective combined modality treatment for early-stage aggressive NHL, with the possibility to definitively cure two thirds of the patients.
KW - Aggressive NHL
KW - Early stage
KW - Long-term follow-up
KW - MACOP-B
UR - http://www.scopus.com/inward/record.url?scp=0034839520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034839520&partnerID=8YFLogxK
M3 - Article
C2 - 11697654
AN - SCOPUS:0034839520
VL - 42
SP - 989
EP - 995
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 5
ER -